- South Korea
- /
- Pharma
- /
- KOSDAQ:A200670
Humedix Co., Ltd.'s (KOSDAQ:200670) biggest owners are individual investors who got richer after stock soared 27% last week
Key Insights
- Humedix's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 51% of the business is held by the top 5 shareholders
- Institutional ownership in Humedix is 13%
Every investor in Humedix Co., Ltd. (KOSDAQ:200670) should be aware of the most powerful shareholder groups. With 46% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, individual investors collectively scored the highest last week as the company hit ₩753b market cap following a 27% gain in the stock.
Let's delve deeper into each type of owner of Humedix, beginning with the chart below.
Check out our latest analysis for Humedix
What Does The Institutional Ownership Tell Us About Humedix?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Humedix already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Humedix's historic earnings and revenue below, but keep in mind there's always more to the story.
We note that hedge funds don't have a meaningful investment in Humedix. Looking at our data, we can see that the largest shareholder is Huons Global Co., Ltd. with 39% of shares outstanding. VIP Research & Management Co., Ltd. is the second largest shareholder owning 5.8% of common stock, and AssetPlus Investment Management Co. holds about 2.4% of the company stock.
Our research also brought to light the fact that roughly 51% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is some analyst coverage of the stock, but it could still become more well known, with time.
Insider Ownership Of Humedix
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our most recent data indicates that insiders own some shares in Humedix Co., Ltd.. It has a market capitalization of just ₩753b, and insiders have ₩12b worth of shares, in their own names. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 46% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Public Company Ownership
Public companies currently own 39% of Humedix stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Humedix (of which 1 is a bit unpleasant!) you should know about.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Valuation is complex, but we're here to simplify it.
Discover if Humedix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A200670
Humedix
Engages in the manufacture and sale of various pharmaceutical products in South Korea.
Moderate growth potential not a dividend payer.
Market Insights
Community Narratives


Recently Updated Narratives

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

The Quiet Giant That Became AI’s Power Grid

Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth
Popular Narratives

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

MicroVision will explode future revenue by 380.37% with a vision towards success
